文献速递中医儿科中药与中成药合理使用

槐杞黄颗粒治疗儿童慢性原发性免疫性血小板减少症的多中心随机双盲安慰剂对照临床研究

The efficacy and safety of Huaiqihuang Granule in the treatment of childhood chronic primary immune thrombocytopenia: a multi-centre, randomized, double-blind, placebo-controlled clinical study ().
PubMed 文献 · J Ethnopharmacol · 2025-12-18

本研究为多中心随机双盲安慰剂对照试验,纳入216例儿童慢性原发性免疫性血小板减少症患者,随访96周,评估槐杞黄颗粒的疗效与安全性。结果显示槐杞黄颗粒组24周总临床有效率71.74%,高于安慰剂组45.65%(p=0.0013),在降低出血分级和血小板反应方面优于安慰剂,两组不良事件相当。

要点

  • 槐杞黄颗粒可提高CITP患儿24周总临床有效率(71.74% vs 45.65%,p=0.0013)。
  • 槐杞黄颗粒在降低出血分级和Achieving血小板反应方面优于安慰剂。
  • 长期治疗安全性良好,不良事件与安慰剂相当。

核心结论

  • 槐杞黄颗粒可改善CITP患儿的临床有效性,尤其是出血程度,且长期治疗安全性良好。

研究设计与样本

  • 双盲治疗期24周,安慰剂组完成24周后转为槐杞黄颗粒开放标签治疗24周,槐杞黄颗粒组继续开放标签治疗24周。

主要发现

  • 槐杞黄颗粒组24周总临床有效率71.74%,高于安慰剂组45.65%(p=0.0013)。
  • 将接受补救治疗的患者数据作为无效或排除分析时,结果相似。
  • 两组不良事件和严重不良事件相当,严重不良事件包括血小板减少(6.9%)、呼吸道感染(5.1%)和出血事件(2.8%)。

关键数值与推荐

  • 24周总临床有效率:槐杞黄颗粒组71.74%,安慰剂组45.65%(p=0.0013)。
  • 严重不良事件发生率:血小板减少6.9%、呼吸道感染5.1%、出血事件2.8%。

临床怎么用

  • 对于儿童慢性原发性免疫性血小板减少症,可考虑使用槐杞黄颗粒以改善出血程度和临床有效率。
  • 长期使用需关注严重不良事件,包括血小板减少、呼吸道感染和出血事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Chronic immune thrombocytopenia (CITP) seriously affects the patients' quality of life. In the real world, a traditional Chinese medicine, Huaiqihuang Granule (HQH) shows certain value in ITP treatment.It primarily comprises Huai'er (Trametes robiniophia Murr), Gouqizi (Lycium chinense Mill), Huangjing (Polygonatum sibiricum F. Delaroche). AIM OF THE STUDY: This study aims to investigate the clinical efficacy and safety of HQH in children with CITP. MATERIALS AND METHODS: A multi-centre, randomized, double-blind, placebo-controlled clinical trial was conducted among 216 children with CITP from June 27, 2017 to October 14, 2023, at 13 hospitals in China. Patients were followed up for 96 weeks. Patients with CITP were treated with HQH or with matching placebo in a randomized, double-blind, 24-week treatment period. Patients who received placebo and completed 24 weeks of treatment switched to receive HQH, and patients treated with HQH in the double-blind period continued HQH during the following open-label 24-week treatment. RESULTS: HQH was superior to placebo in decreasing the bleeding grade and achieving a platelet response. The total clinical effectiveness rate of HQH group (71.74 % in 24-week) was higher than that of the placebo group (45.65 % in 24-week, p = 0.0013). The result was similarly seen when the data of patients with rescue treatment was analyzed as ineffectiveness or excluded. AEs and serious AE was comparable between the two groups. The severe AEs included thrombocytopenia (6.9 %), respiratory tract infection (5.1 %) and hemorrhagic episodes (2.8 %). CONCLUSIONS: In CITP children, HQH can improve the clinical effectiveness especially the degree of bleeding, and shows good safety even with long-term treatment.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Han J, Fu Q, Liang C, et al. The efficacy and safety of Huaiqihuang Granule in the treatment of childhood chronic primary immune thrombocytopenia: a multi-centre, randomized, double-blind, placebo-controlled clinical study (). J Ethnopharmacol. 2025. PMID: 41421405. doi:10.1016/j.jep.2025.121050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。